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Summary
Objective

To investigate the clinical- and cost-effectiveness at 2-year follow-up of providing individual, supervised
exercise physiotherapy and/or manual physiotherapy in addition to usual medical care.

Method

People with hip or knee osteoarthritis meeting the American College of Rheumatology clinical diagnostic criteria
were randomised (1:1, concealed, assessor-blinded) to four groups: usual medical care; supervised exercise
physiotherapy; manual physiotherapy; or combined exercise and manual physiotherapy. Physiotherapy group
participants were provided 10 50-min treatment sessions including booster sessions at 4 and 13 months, in
addition to usual care. The primary outcome at 2-year follow-up was incremental cost-utility ratio (ICUR) of each
physiotherapy intervention in addition to usual care, compared with usual care alone, from the health system
and societal perspectives. To allow interpretation of negative ICURs, we report incremental net benefit (INB).
The primary clinical outcome was the Western Ontario and McMaster Osteoarthritis Index (WOMAC).

Results

Of 206 patients, 186 (90·3%) were retained at 2-year follow-up. Exercise physiotherapy and manual
physiotherapy dominated usual care, demonstrating cost savings; combined therapy did not. Exercise
therapy had the highest incremental net benefits (INBs), statistically significant at all willingness-to-pay (basecase: societal New Zealand (NZ)$6,312, 95%CI 334 to 12,279; health system NZ$8,065, 95%CI 136 to 15,994).
Clinical improvements were superior to usual care only in the exercise physiotherapy group
(−28.2 WOMAC points, 95%CI -49.2 to −7.1). No serious adverse events were recorded.

Conclusion

Individually supervised exercise therapy is cost-effective and clinically effective in addition to usual medical care
at 2-year follow-up, and leads to cost savings for the health system and society.

Trial registration

Prospectively registered with the Australian NZ Clinical Trials Registry, reference ACTRN12608000130369.

Introduction
Hip and knee osteoarthritis (OA) are typically characterized by a long period of progressively increasing
morbidity between the first development of clinical symptoms and, in many cases, the eventual need for joint
replacement surgery1, 2, 3. During this time, clinical guidelines generally recommend the use of conservative nonsurgical, non-pharmacological treatment options, primarily exercise therapy, as first-line treatments4, however
such therapies are under-utilized.5

The aims of the Management of Osteoarthritis (MOA) trial were to investigate the incremental clinical- and costeffectiveness of an exercise therapy programme and/or a manual therapy programme informed by the best
available evidence, delivered in addition to usual medical care, compared to usual medical care only for the
management of hip and knee OA6. We hypothesised that such interventions may provide incremental benefits
over usual medical care alone in terms of clinical outcomes and value for money. The pre-planned primary
outcome at the 2-year endpoint of this trial was cost-effectiveness of the physiotherapy programmes compared
with usual care6. This study reports on the cost-effectiveness and clinical outcomes of the MOA trial
interventions using 2-year follow-up data to investigate the long-term economic and health gains attributable to
providing individual, supervised physiotherapy in addition to usual medical care.

Methods
Study design and participants

The MOA trial was a factorial randomised controlled trial of exercise therapy and manual therapy, in addition to
usual medical care, for patients with knee or hip OA. Pre-specified protocols for both the trial and the economic
evaluation have been published6, 7. The primary outcome at 2-year follow-up (specific aim 36) was a parallel
group economic evaluation of each intervention compared with usual care only.
Details of participant recruitment, eligibility and exclusion criteria, and participant flow have been reported
previously6, 8. Briefly, patients with suspected hip or knee OA were recruited via two sources: a) patients
attending general medical practitioners (GPs) in Dunedin, New Zealand (NZ); and b) patients referred by their GP
to attend a first specialist consultation by an orthopaedic surgeon at the Department of Orthopaedic
Surgery outpatient clinic (Dunedin Hospital, New Zealand) for assessment of hip or knee OA, but not meeting
the priority threshold for offer of joint replacement surgery.
Consenting participants were required to meet the American College of Rheumatology clinical criteria for hip or
knee OA9, have no previous history of rheumatoid arthritis or previous hip or knee joint replacement surgery at
the time of study enrolment, no recent (within 30 days) initiation of opioid or corticosteroid intervention, and
able to complete the proposed course of intervention and follow-up.

Randomisation and masking

To ensure allocation concealment, a research manager (non-clinician) randomly assigned participants, using the
TENALEA online computer-generated randomisation service10, after baseline assessment and enrolment by the
outcome assessors. Randomisation was stratified by joint affected (hip or knee), in equal ratio and randomly
varying block sizes6, to one of four intervention groups: usual care only; physiotherapist-delivered exercise
therapy in addition to usual care; physiotherapist-delivered manual therapy in addition to usual care; and a
combination of both the exercise therapy and manual therapy in addition to usual care. Assessments were
conducted by one of 3 study assessors blinded to group allocation. Physiotherapy interventions were provided
by physiotherapists not involved in outcome assessment. GPs and orthopaedic surgeons were blinded to
patients’ group allocation.6, 8

Procedures

In each of the three treatment groups, participants attended seven physiotherapy sessions of approximately
50 min each over a 9-week programme, as well as two additional ‘booster’ sessions at week 16, and a final
booster session at week 54. The treatment protocols have been reported earlier (Web Appendix 1).8, 11
The usual care control group received no trial physiotherapy. We measured, by participant self-report
questionnaire, all medical and other healthcare services consumed by all participants during the trial, including
any reported access to non-trial physiotherapy. Each participant's GP, blinded to group allocation, was

requested to avoid referral to physiotherapy within the 9-week intervention phase, to avoid contamination, but
we did not require physiotherapy be withheld throughout the follow-up period of the trial. All participants
recruited from secondary care continued to receive their usual care by consultant orthopaedic surgeons blind to
group allocation. Participation in the trial had no bearing on patients' prioritisation for, or access to, joint
replacement surgery. All participants continued to receive the usual routine care offered by their own GP and
other healthcare providers throughout the trial and follow-up. In this way, the trial evaluates the effectiveness
of physiotherapy care in addition to usual care, and provides a real-world, policy-relevant comparator on which
to base value-for-money decisions regarding health services provision.

Outcomes

Assessors administered patient-reported outcome questionnaires and performed clinical assessments at
baseline, 9 weeks, 6 months, 1 year, and 2 years. Economic variables were self-reported by patients at baseline
and at 6 months, 1- and 2- years.
The primary outcome at the 2-year endpoint of this trial was incremental cost-effectiveness of the
physiotherapy programmes6. The primary effectiveness outcome for the economic evaluation was the qualityadjusted life years (QALYs) experienced over the 2-year follow-up period, assessed using the SF-6D, a sixdimension health-related quality of life (HRQoL) instrument derived from the 12-item Medical Outcomes StudyShort Form 12 (SF-12v2). Utility weights derived from the UK general population were applied to SF-6D profiles
to estimate QALYs12. We calculated QALYs by using time-weighted averages at the beginning and end of each of
the 6-month, 1-year, and 2-year measurement periods. QALYs and costs from the second year of follow-up were
discounted by an annual rate of 3.5 percent.13
Total OA-related costs were estimated from both the health system and societal perspectives. Healthcare costs,
other related expenditures, and lost productivity resulting from OA to participants and their friends and family
members was collected using the Otago Costs and Consequences Questionnaire (OCC-Q) instrument validated
for use in the OA population14. Total joint replacements were verified against the NZ National Joint Register.
Resource use within the healthcare sector was valued using 2009 unit costs derived from various sources
(see Web Appendix 2). All costs are expressed in 2009 NZ dollars, exclusive of Goods and Services Tax.
Productivity losses associated with inability to work due to OA were valued using the friction cost method,
applying a 6-month friction period, and are reported separately. Individual participant wage rates were applied
to time lost.
The primary clinical outcome was change in the composite Western Ontario and McMaster osteoarthritis index
(WOMAC) between baseline and 2-year follow-up. Secondary outcome measures included measures of pain,
physical function, and global rating of change. Participants were classified as responders or non-responders
according to the Outcome Measures in Rheumatoid Arthritis Clinical Trials – Osteoarthritis Research Society
International (OMERACT-OARSI) responder criteria at 2 years: ≥50% improvement in pain or function and an
absolute improvement of ≥20; or ≥20% improvement and an absolute improvement of ≥10 in at least two out of
three of pain, function, and global assessment15, using the WOMAC pain and function subscales and the global
rating of change instrument. Adverse events were recorded and classified.

Statistical analysis

All data analyses were done in Stata (Station, TX, USA) version 14.2 by a health economist (RW) not involved in
the trial design or conduct. As pre-specified in the trial protocol, all analyses were conducted according to
intention-to-treat, and results are reported separately for the full sample of participants and for those
participants who did not receive the potentially confounding, non-study intervention of hip or knee replacement
during the trial and follow-up period.6

Both item-level data missingness and censoring due to loss to follow-up were addressed via multiple imputation
using the MI package in Statav14.2. Data were treated as missing at random (MAR). Patterns of missing data and
the distribution of responses were examined to determine appropriate imputation equations for each variable.
Data from three participants who died during the follow-up period were treated as complete cases with known
costs and effects in the economic analysis, and excluded from the analysis of clinical outcomes at 2-year followup. Thirty-six imputed data sets were created, and variable distributions examined against observed data.
We calculated incremental cost-utility ratios (ICURs) and incremental net benefits (INBs) at the willingness to
pay thresholds of one, two, and three times GDP per capita (NZ$42,981, NZ$85,962, and NZ$128,943,
respectively)16. incremental net benefit (INB) analysis, not included in the initial protocol7, was added to solve
difficulties with the interpretation of ambiguous negative ICURs, and as such is a best-practice
recommendation17. INB represents the value of an intervention in monetary terms given a willingness-to-pay
threshold for the unit of benefit (i.e., QALY), and is calculated as [incremental benefit x
threshold] minus incremental cost. Confidence intervals (CIs) around INB estimates were calculated around
sample mean incremental costs and QALYs18. Confidence ellipses were constructed on the cost-effectiveness
plane to illustrate the impact of sample uncertainty on the cost-effectiveness of each intervention relative to
usual care. All analyses were undertaken from both the societal and health system perspectives. Results were
adjusted for age, sex, primary OA joint (hip or knee), body mass index, number of years since symptom onset,
and baseline WOMAC score, quadriceps muscle strength, mental health, self-efficacy, and SF-6D score, as prespecified in the analysis protocol6. Additional sensitivity analyses were conducted by (1) restricting the sample to
complete cases only, to evaluate the impact of the imputation of censored data; and (2) excluding productivity
losses from the analysis from the societal perspective.7
The primary clinical outcome analysis investigated firstly the main effects of the factorial design and interaction,
and secondly the between-group treatment effect, compared with usual care, of each of the three interventions
on change in the WOMAC composite score between baseline and 2-year follow-up6. Both adjusted and
unadjusted analyses were undertaken; adjusted analyses were primary, performed using analysis of
covariance controlling for the same set of covariates (except baseline SF-6D value) as the economic analysis.
Secondary clinical outcomes are reported as means and 95% CIs of the change from baseline to 2-year followup, by intervention group. Analyses were adjusted for the same set of confounding variables as above, using
linear (pain, physical function, and global change) and logistic (OMERACT-OARSI response) regression models.

Results
206 participants aged between 37 and 92 years (mean 66 years) were recruited (Fig. 1) between 23 March 2008
and 30 March 2009, and are described in Table I as previously8. 203 were surviving at 2-year follow-up. All 206
participants completed the OCC-Q and SF-12 questionnaires at baseline, 192 (93·2%) at 6-months, 192 (93·2%)
at 1-year, and 186 (90·3%) at 2-years. 180 (87·4%) completed the questionnaires at all three follow-up points.
Seventy-one participants (34·5%) received either a hip or knee joint replacement during the 2-year follow-up
period.

Fig. 1. Profile of the Management of Osteoarthritis (MOA) trial.
Table I. Characteristics of participants at entry to the trial

Demographic
Men, n (% of group)
Women, n (% of group)
Age (years)
Body mass index (kg/m2)
Clinical
WOMAC score (range 0–240, lower
scores represent less pain, stiffness
and disability)
Timed up and go test (s)
30-s sit to stand test (no. of stands):
40 m self-paced walk time (s):
Pain intensity score (range 0–10,
higher scores represent more pain)
Quadriceps muscle strength (kg/kg
body mass)
Duration since first diagnosis of
osteoarthritis (years)
Mental health (depression screening
test) score indicates low risk of
depression, n (% of group)
Hip osteoarthritis, n (% of group)
Knee osteoarthritis, n (% of group)

Usual care
control
(n = 51)

Usual care plus
manual
therapy
(n = 54)

Usual care plus
exercise
therapy
(n = 51)

Usual care plus combined
exercise + manual therapy
(n = 50)

26 (51.0)
25 (49.0)
66.1 (10.7)
29.5 (5.8)

26 (48.1)
28 (51.9)
67.3 (10.2)
29.2 (5.9)

19 (37.3)
32 (62.7)
66.9 (8.2)
29.3 (6.0)

21 (42.0)
29 (58.0)
66.0 (8.9)
30.1 (5.4)

93.8 (52.8)

114.8 (56.3)

95.5 (57.3)

99.1 (48.8)

7.69 (3.26)
9.65 (4.29)
33.21
(12.42)
3.1 (2.0)

7.68 (3.07)
9.80 (4.54)
33.67 (10.18)

7.50 (3.14)
10.39 (4.37)
33.42 (11.14)

6.88 (2.33
10.60 (3.79)
30.93 (8.37)

4.2 (2.3)

3.5 (2.0)

4.0 (2.1)

0.21 (0.12)

0.20 (0.09)

0.20 (0.07)

0.20 (0.08)

2.8 (1.3)

2.5 (1.4)

2.6 (1.4)

2.9 (1.3)

26 (51.0)

27 (50.9)

27 (52.9)

28 (56.0)

23 (45.1)
28 (54.9)

24 (44.4)
30 (55.6)

22 (43.1)
29 (56.9)

21 (42.0)
29 (58.0)

Both hip and knee
osteoarthritis, n (% of group)

13 (25.5)

12 (22.2)

10 (19.6)

17 (34.0)

Values are mean (SD) unless specified otherwise. WOMAC= Western Ontario and McMaster osteoarthritis index.
From the perspective of the NZ health system, the programme of manual therapy in addition to usual care had a
mean incremental cost over 2 years of $1,011 relative to usual care only, while the combined manual
and exercise therapy had an incremental cost of $1,635 (Table II). The exercise therapy intervention was costsaving relative to usual care (-$935 per patient). From the societal perspective, both manual therapy and
exercise therapy were cost-saving (incremental costs of -$2,184 and -$3,530 respectively). Combined therapy
had an incremental cost of $210 relative to usual care only. Excluding productivity costs from the societal
perspective, only exercise therapy was cost-saving relative to usual care (-$1795; Table II).

Table II. Mean (SD) costs and health outcomes through 2 years in base case and sensitivity analyses∗
Cost outcomes
MOA trial programme
Public health system
costs
Private health system
costs
Costs to patient, family,
and friends
Productivity costs
Total New Zealand
health system costs
Complete cases only
(n = 183)
No hip or knee
replacement (n = 135)
Total societal costs
Complete cases only
(n = 183)
Excluding productivity
costs
No hip or knee
replacement (n = 135)
Health outcomes
QALYs
Complete cases only
(n = 183)
No hip or knee
replacement (n = 135)

Usual care
control

Usual care plus
manual therapy

Usual care plus
exercise therapy

Usual care plus combined
exercise + manual therapy

0
7,410

(0)
(12,239)

486
9,047

(204)
(14,915)

503
6,851

(185)
(10,572)

507
7,248

(187)
(10,600)

1,863

(6,600)

752

(2,655)

984

(3,648)

3,154

(7,899)

1,477

(2,968)

806

(1,146)

618

(583)

929

(1,206)

4,620
9,273

(13,212)
(13,957)

2,096
10,284

(6,184)
(14,840)

2,884
8,338

(9,853)
(10,976)

3,742
10,908

(9,793)
(11,875)

9,777

(14,419)

9,444

(14,255)

8,266

(10,820)

10,888

(11,977)

3,299

(6,936)

4,904

(14,606)

1,281

(2,588)

2,669

(7,415)

15,370
15,551

(20,447)
(20,521)

13,187
12,183

(16,808)
(16,223)

11,840
11,564

(17,336)
(17,270)

15,580
15,433

(18,102)
(18,134)

10,750

(14,281)

11,090

(15,228)

8,955

(11,113)

11,837

(12,352)

9,689

(18,425)

6,586

(15,871)

2,748

(6,778)

4,327

(9,497)

1.31
1.31

(0.286)
(0.292)

1.39
1.40

(0.210)
(0.208)

1.46
1.44

(0.234)
(0.221)

1.38
1.40

(0.186)
(0.173)

1.32

(0.315)

1.39

(0.224)

1.51

(0.231)

1.41

(0.186)

∗ All participants (n = 206); QALYs = quality-adjusted life years.

Restricting the sample to complete cases only (n = 183), manual therapy and exercise therapy were cost-saving
from the health system perspectives, while all interventions were cost-saving from the societal perspective.
Among those without joint replacement surgery during the trial (n = 135), exercise therapy and combined
therapy were cost-saving from both the health system and societal perspectives, while manual therapy was
cost-saving from the societal perspective only.
All three physiotherapy interventions produced clinically significant gains in QALYs lived over the 2-year followup compared with usual care (Table II)19. Exercise therapy produced the largest gains (0·15 QALYs), while manual
therapy and combined therapy both produced gains of 0·07 QALYs. Results were similar for both the complete
cases sub-sample and the sample of participants without joint replacement surgery during the trial.
Cost-utility analyses revealed that all three interventions were cost-effective relative to usual care only at
willingness to pay thresholds of one, two, and three times GDP per capita (Table III). After adjusting for
covariates, both exercise therapy and manual therapy dominated usual care from both the societal and health
system perspectives. Exercise therapy had the highest probability of cost-effectiveness in almost all scenarios
(Fig. 2).

Table III. Incremental cost-utility ratios and incremental net monetary benefits for manual therapy, exercise therapy, and combined therapy

relative to usual care only, base case and sensitivity analyses∗

Incremental costutility ratio
Base case
NZ health system
perspective
Societal
perspective
No hip or knee
replacement
NZ health system
perspective
Societal
perspective
Complete cases
only
NZ health system
perspective
Societal
perspective
Excluding
productivity costs
Societal
perspective
Incremental net
benefit (95% CI)
Base case
NZ health system
perspective
1×GDP/capita

Manual therapy
relative to usual
care

Exercise therapy
relative to usual
care

Combined exercise + manual
therapy relative to usual care

−7,138

†

−3,657

†

35,566

−43,475

†

−16,616

†

20,832

−9,753

†

−3,876

†

†

11,932
−34,075

†

−39,637

†

−55,233

−20,135

†

−10,225

†

32,513

−50,501

†

−20,628

†

22,658

−14,789

†

−10,068

†

27,709

4,480

(-1,595 to
10,554)

6,312

(344 to 12,279)

464

(-5,695 to
6,624)

2×GDP/capita

8,322

(224 to 16,419)

12,128

(4,137 to
20,119)
(7,440 to
28,449)

3,156

3×GDP/capita

12,163

17,945

Societal perspective
1×GDP/capita

(1,542 to
22,785)

7,728

(-494 to 15,949) 8,065

(136 to 15,994)

1,387

2×GDP/capita

11,570

(1,739 to
21,400)
(3,402 to
27,421)

(4,324 to
23,440)
(7,947 to
31,449)

4,079

3×GDP/capita

15,411

No hip or knee
replacement
NZ health system
perspective
1×GDP/capita

3,422

(-3,334 to
8,144
10,179)
(-1,663 to
14,783
17,983)
(-471 to 26,267) 21,421

(1,800 to
14,489)
(5,374 to
24,192)
(8,494 to
34,347)

4,621

13,099

(-2,618 to
11,860)
(-1,488 to
19,208)
(-909 to 27,106)

2×GDP/capita

8,160

3×GDP/capita

12,898

Societal perspective
1×GDP/capita

8,494

(-1,043 to
18,030)
(1,411 to
25,052)
(3,140 to
32,798)

12,760

(4,019 to
21,501)
(8,312 to
30,484)
(11,905 to
40,168)

9,686

(234 to 19,138)

2×GDP/capita

13,231

13,925

(1,961 to
25,888)
(2,953 to
33,374)

3×GDP/capita

17,969

Complete cases
only
NZ health system
perspective
1×GDP/capita

6,330

(17 to 12,644)

6,890

(775 to 13,004)

645

2×GDP/capita

10,641

(2,181 to
19,102)

12,455

(4,202 to
20,709)

3,294

13,882
19,698

19,398
26,036

5,848

6,771

8,860

18,163

(-5,049 to
11,362)
(-4,912 to
16,609)
(-6,673 to
9,447)
(-5,674 to
13,833)
(-5,244 to
18,787)

(-5,764 to
7,054)
(-5,260 to
11,848)

3×GDP/capita

14,952

18,021

(7,135 to
28,907)

5,943

Societal perspective
1×GDP/capita

(3,834 to
26,071)

(-5,281 to
17,166)

9,376

8,237

(202 to 16,271)

1,252

2×GDP/capita

13,687

13,802

17,998

Excluding
productivity costs
Societal perspective
1×GDP/capita

(3,995 to
23,610)
(7,224 to
31,511)

3,901

3×GDP/capita

(1,124 to
17,628)
(3,644 to
23,730)
(5,590 to
30,406)

(-7,070 to
9,574)
(-6,216 to
14,018)
(-5,946 to
19,046)

5,164

(-1,053 to
11,380)
(784 to 17,227)

7,179

19,368

6,550

(1,068 to
957
(-5,339 to
13,290)
7,252)
2×GDP/capita
9,005
12,996
(4,880 to
3,649
(-4,679 to
21,112)
11,976)
3×GDP/capita
12,847
(2,118 to
18,812
(8,200 to
6,341
(-4,528 to
23,576)
29,425)
17,209)
Results are adjusted for age, sex, primary OA joint, baseline WOMAC score, baseline SF-6D HRQoL, body mass index, symptom duration, quadriceps
muscle strength, depression, and self-efficacy.
∗ All participants (n = 206).
† Treatment dominates usual care only.

Fig. 2. Cost-effectiveness plane (95% Confidence intervals (CIs)) and cost-effectiveness acceptability curves for the
MOA physiotherapy treatments relative to usual care in terms of cost per QALY gained from the perspectives of the New
Zealand (NZ) health system and society for participants without joint replacement surgery during the trial (n = 135) and all
participants (n = 206).
INBs were positive for all three physiotherapy interventions at all willingness to pay thresholds (Table III).
Exercise therapy had the highest INBs, with 95% CIs strictly greater than zero at all willingness to pay thresholds.
Manual therapy had INBs significantly greater than zero at the 2×GDP per capita (health sector perspective) and
the 2×GDP per capita (societal perspective) thresholds, while INBs for combined therapy did not reach statistical
significance.
In the subgroup without joint replacement during the trial, all three MOA trial interventions were highly costeffective relative to usual care from both the societal and health system perspectives; exercise therapy again
dominated usual care from both the societal and health system perspectives, while manual therapy dominated
usual care from the societal perspective only. Exercise therapy was again the intervention with the highest INBs,
which were significantly greater than zero, at the 95% confidence level, at all willingness to pay thresholds.
Manual therapy and combined therapy had similar INBs in this sub-sample; however these were significantly
greater than zero from the societal perspective only, at the 1×(combined therapy) and 2×(manual therapy) GDP
per capita thresholds and above.
Sensitivity analyses showed that, in the complete case analysis, the INBs were generally slightly higher than the
base case analysis. Both the manual therapy and exercise therapy interventions had INBs statistically
significantly greater than zero at all willingness-to-pay thresholds, from both the societal and health system
perspectives. The combined therapy intervention remained cost-effective, but did not reach statistical
significance.
Excluding productivity costs from the societal perspective slightly reduced the cost-effectiveness of all three
interventions. All interventions, however, remained highly cost-effective relative to usual care only, with INBs
significantly greater than zero for exercise therapy (at all willingness-to-pay thresholds) and manual therapy (at
the 2×GDP per capita threshold and above).
The clinical outcomes of all three treatment groups showed clinically significant reductions of
>28 WOMAC points from baseline to 2-year follow-up (Table IV, Fig. 3(a)). In the factorial analysis, exercise

therapy was superior to no exercise therapy (−28·2 WOMAC points, 95% CI -49·2 to −7·1), manual therapy was
not significantly better than no manual therapy (−6·3, WOMAC points, 95% CI -28·1 to 15·5) in the main
intention-to-treat analysis, with a non-significant detrimental interaction effect (+13·7 WOMAC
points, p = 0·368). Compared with usual care only, exercise therapy provided a clinically-significant gain in
WOMAC (Table IV), while manual therapy and combined therapy did not. Improvement over time was observed
in the usual care only group, however this did not reach the clinical significance threshold (−22·5 WOMAC
points, 95% CI -37·5 to −7·5), and disappeared after eliminating the effects of joint replacement surgery
(Table IV). The number needed to treat (NNT) to gain one additional OMERACT-OARSI responder, compared
with usual care only, was 5 (2.6–73.7) for exercise therapy and 5 (2.4–23.8) for combined exercise- and manual
therapy. For manual therapy the NNT was equivocal, at 7 with a lower 95% confidence bound of 2.0 extending
to a number needed to harm of 22.2.

Table IV. Mean (SD) WOMAC scores at 2-year follow-up and change in score from baseline∗
Usual
care
control
(n = 50)

Usual care
plus manual
therapy
(n = 53)

Unadjusted
WOMAC score at
2 years
All participants
(n = 203)

Betweengroup diff.
(95%CI)

Usual care
plus
exercise
therapy
(n = 51)

Usual care plus
combined
exercise + manual
therapy (n = 49)

Betweengroup diff.
(95%CI)

76.7

(62.1)

74.2

(58.4)

−2.4 (−25.0
to 20.1)

48.9

(45.2)

No hip or knee
replacement
(n = 132)
Within-group
change in
WOMAC score
from baseline
All participants
(n = 203)

93.3

(62.8)

84.7

(57.3)

−8.6 (−36.9
to 19.7)

54.7

(47.5)

−17.8

(66.0)

−42.4

(63.5)

−45.6

(58.7)

No hip or knee
replacement
(n = 132)
Adjusted
WOMAC score at
2 years
All participants
(n = 203)

11.8

(46.0)

−20.7

(48.9)

−24.7
(−49.9 to
0.5)
−32.5
(−56.8
to −8.1)

−20.4

(43.9)

78.5

(51.5)

72.2

(53.8)

−6.3 (−28.1
to 15.5)

50.3

(43.0)

No hip or knee
replacement
(n = 132)
Within-group
change in
WOMAC score
from baseline

94.4

(43.2)

74.8

(42.7)

−19.6
(−43.8 to
4.6)

63.6

(37.5)

Betweengroup diff.
(95%CI)

−27.8
(−50.1
to −5.5)
−38.6
(−66.0
to −11.2)

58.9

(51.7)

77.9

(54.0)

−27.8
(−52.9
to −2.7)
−32.2
(−55.6
to −8.8)

−38.5

(58.4)

−11.4

(50.2)

−28.2
(−49.2
to −7.1)
−30.8
(−53.5
to −8.0)

57.7

(47.8)

77.6

(45.2)

−17.7
(−40.9 to
5.5)
−15.4
(−45.5 to
14.8)

−20.7
(−46.6 to
5.2)
−23.2
(−49.2 to
2.8)

−20.7
(−43.0 to
1.5)
−16.8
(−42.9 to
9.4)

All participants
(n = 203)

−22.5

(51.5)

−28.7

(53.8)

−6.3 (−28.1
to 15.5)

−50.6

(43.0)

No hip or knee
replacement
(n = 132)

6.8

(43.2)

−12.8

(42.7)

−19.6
(−43.8 to
4.6)

−24.0

(37.5)

−28.2
(−49.2
to −7.1)
−30.8
(−53.5 to
8.0)

−43.2

(47.8)

−10.0

(45.2)

−20.7
(−43.0 to
1.5)
−16.8
(−42.9 to
9.4)

*Of participants surviving at 2 year follow-up (n = 203 of 206, 98.5%). Negative change represents improvement. Adjusted results: linear regression
model adjusting for age, sex, primary OA joint, baseline WOMAC score (scale 0–240), body mass index, symptom duration, quadriceps muscle strength,
depression, and self-efficacy. WOMAC= Western Ontario and McMaster osteoarthritis index.

Fig. 3. Course of outcomes by group from baseline through 2-year follow-up. 3a = Primary intention-to-treat analysis

(n = 206); 3b = subgroup analysis of participants who did not undergo joint replacement surgery during follow-up (n = 132).
Bars represent time-specific estimates with 95% confidence intervals, adjusted for age, sex, primary OA joint,
baseline WOMAC score, body mass index, symptom duration, quadriceps muscle strength, depression, and self-efficacy.
WOMAC= Western Ontario and McMaster osteoarthritis index (scale 0–240).

For the sample of participants without joint replacement surgery during the trial, the usual care group showed a
non-significant worsening of WOMAC points over the period (+6.8 WOMAC points, 95% CI -7·2 to 20·8)
[Fig. 3(b)]. In the factorial analysis, exercise therapy was superior to no exercise therapy (−30·8 WOMAC points,
95% CI -53·5 to −8·0), manual therapy was not significantly better than no manual therapy (−19·6, WOMAC
points, 95% CI -43·8 to 4·6), with a large but marginally non-significant detrimental interaction effect (+33·6
WOMAC points, p = 0·054). Compared with usual care only, exercise therapy again provided a clinicallysignificant gain in WOMAC (Table IV), while manual therapy and combined therapy did not. The change in
WOMAC scores in each treatment group was similar for those with hip OA and those with knee OA (Web
Appendix 3).
In secondary analyses, the physical performance tests showed non-significant worsening in the usual care group,
consistent improvements in the exercise therapy group, and inconsistent changes in the other intervention
groups (Table V). Exercise therapy provided significant gains over usual care at 2 years follow-up in the Timed
Up-and-Go test and 40 m fast-paced walk test. Pain intensity scores improved over time in all three intervention
groups; in the usual care group, scores improved within the full sample, but worsened slightly for those without
a joint replacement during the follow-up period. The proportion of OMERACT-OARSI responders was higher in
all three intervention groups than in the group receiving usual care only, and statistically significant in the
exercise therapy and combined therapy groups (full sample only) compared with usual care alone.

Table V. Changes in secondary outcomes from baseline to 2-year follow-up.∗ Mean (SD) unless specified otherwise
Usual care Usual care plus
Between-group diff.
Usual care
Between-group
Usual care plus
control
manual therapy
(95%CI)
plus exercise
diff. (95%CI)
combined
therapy
exercise + manual
therapy
Timed up and go test
(s)†
No hip or knee
1.32
1.07
−0.26
−0.81
−2.14
0.09
replacement
(n = 132)
(0.35
(0.02 to 2.12)
(-1.74 to 1.23)
(-1.77 to
(-3.52 to −0.78) (-1.07 to 1.25)
to 2.30)
0.14)
All participants
0.53
0.44
−0.09
−1.37
−1.89
0.01
(n = 203)
(-0.31 to
(-0.39 to 1.26)
(-1.28 to 1.10)
(-2.17
(-3.05 to −0.73) (-0.85 to 0.86)
1.36)
to −0.57)
30s sit to stand test
(no. of stands)‡
No hip or knee
−0.50
−0.17
0.33
1.65
2.15
1.29
replacement
(n = 132)
(-2.12 to
(-1.87 to 1.53)
(-2.08 to 2.75)
(0.04
(-0.18 to 4.47)
(-0.65 to 3.23)
1.12)
to 3.23)
All participants
−0.08
0.36
0.44
0.43
0.50
1.39
(n = 203)
(-1.48 to
(-1.04 to 1.76)
(-1.59 to 2.46)
(-0.93 to
(-1.46 to 2.46)
(-0.06 to 2.84)
1.33)
1.78)
40 m self-paced walk
time (s)†
No hip or knee
4.20
−0.24
−4.44
−3.85
−8.04
1.17
replacement
(n = 132)
(-0.05 to
(-4.97 to 4.50)
(-10.87 to 2.00)
(-8.11 to
(-14.17
(-4.00 to 6.35)
8.44)
0.42)
to −1.92)
All participants
1.27
−1.48
−2.75
−6.77
−8.04
−0.85
(n = 203)
(-2.20 to
(-5.01 to 2.05)
(-7.74 to 2.23)
(-10.11
(-12.88
(-4.54 to 2.84)
4.74)
to −3.42)
to −3.20)

Between-group
diff. (95%CI)

−1.24
(-2.78 to 0.31)
−0.52
(-1.72 to 0.69)

1.79
(-0.82 to 4.40)
1.47
(-0.57 to 3.51)

−3.02
(-9.88 to 3.83)
−2.12
(-7.24 to 2.99)

No hip or knee
replacement
(n = 132)
All participants
(n = 203)
OMERACT-OARSI
responders, no.
(% of group)
No hip or knee
replacement
(n = 132)
All participants
(n = 203)

All participants
(n = 203)
Complete cases
(n = 183)

0.19

−1.07

Pain intensity score
(range 0–10, negative
scores indicate
reduced pain)
−1.26

(-0.58 to
0.95)
−1.01

(-1.91 to −0.24)

(-2.42 to −0.10)

−1.65

−0.63

(-1.66
to −0.36)

(-2.29 to −1.00)

(-1.57 to 0.30)

9 (26.9%)

15 (48.3%)

21 (44.4%)

−0.89

−1.07

−0.37

−0.55

(-1.66
to −0.12)
−1.92

(-2.18 to 0.03)

(-1.29 to 0.56)

(-1.79 to 0.68)

−0.91

−1.78

−0.77

(-2.55
to −1.29)

(-1.83 to 0.01)

(-2.45 to −1.10)

(-1.72 to 0.19)

2.85 (0.87 to 9.36)

17 (48.3%)

2.85
(0.89 to 9.07)

12 (38.9%)

1.84 (0.53
to 6.45)

30 (51.5%)

1.39 (0.57 to 3.37)

33 (66.4%)

32 (67.1%)

2.91
(1.14 to 7.41)

13 (27.3%)

19 (29.3%)

Joint replacement
surgeries, no. (% of
group)
1.14 (0.41 to 3.11)

2.80 (1.12
to 6.98)

17 (35.4%)

22 (47.0%)

13 (28.3%)

15 (31.9%)

1.19 (0.49 to 2.89)

15 (32.6%)

1.66 (0.61
to 4.52)
1.22 (0.51
to 2.99)

3.18 (1.14
to 8.87)
1.93 (0.80
to 4.63)

Odds ratio (CI)

19 (43.2%)

Results (except for counts of OMERACT-OARSI respondents and joint replacement surgeries) are adjusted for age, sex, primary OA joint, baseline WOMAC score, body
mass index, symptom duration, quadriceps muscle strength, depression, and self-efficacy.
∗Of participants surviving at 2 year follow-up (n = 203 of 206, 98.5%).
†Negative times represent shorter time to complete, indicating improvement.
‡Positive values represent more repetitions, indicating improvement.

The number of joint replacement surgeries was significantly greater in the combined therapy group compared
with usual care (Table V). No serious adverse events associated with trial interventions were recorded.

Discussion
This study has shown that providing physiotherapist-delivered, individualised programmes of exercise
therapy and/or manual therapy in addition to usual care for the treatment of hip and knee osteoarthritis was
cost-effective relative to usual care only, from both the societal and the narrower health system perspectives. In
particular, the programme of exercise therapy was found to be cost-saving to the health system and society over
2 years, resulted in the largest health utility gains, and provided INBs significantly greater than zero at 95%
confidence levels, in the base case and all sensitivity analyses, at all willingness to pay thresholds. These results
imply that if health systems were to provide access to high-quality, individually supervised
exercise physiotherapy intervention programmes in addition to usual care, cost savings may be reaped through
reduced healthcare consumption and raised productivity.
The main strengths of this trial were its pragmatic design, utilizing a real-world comparison of usual, GP-led
medical care, and its adequate sample size and statistical power, low loss to follow-up, comprehensive cost
data, and the informativeness of the long-term (2-year) follow-up. This allowed an externally-valid investigation
of the incremental effects and value-for-money of providing ancillary health services in addition to usual care. A
limitation of economic evaluations alongside clinical trials is that sample size is typically calculated for the
primary clinical outcome, leaving the economic evaluation underpowered. Our study turned out to be
sufficiently powered to find statistical significance at the 95% confidence level of INBs for the most clinically
effective intervention, that was robust to all sensitivity analyses. Other limitations included the fact that joint
replacement surgery was non-randomised co-intervention that has the potential to bias the effects of the trial
interventions; to clarify this, we planned a priori to conduct secondary subgroup analyses of participants who
did not undergo joint replacement surgery6. The observation of higher rates of joint replacement surgery in the
combined therapy group after adjusting for covariates (not significant in the other two physiotherapy groups)
was unexpected and may be due to chance, given that GPs and orthopaedic surgeons were blinded to group
allocation, but as surgery is the highest cost item this had the potential to bias the results. Any bias in regard to
cost-effectiveness would, however, have been in favour of the usual care group, which was shown in the results
to be dominated by the three intervention groups. The healthcare costs collected were restricted to only OArelated utilisation; given that costs relating to other comorbidities were not accounted for, this approach likely
provides only a limited perspective, which may have resulted in under-estimation of cost-effectiveness.
Generalizability of cost-effectiveness results between countries is limited by six key threats: demography
and epidemiology of the disease; clinical practice patterns and conventions; healthcare provision; relative price
levels; opportunity costs of resources; and consumer health state valuation preferences.20 We consider these
threats as minimal in regard to osteoarthritis among British Commonwealth health systems, and we used UK
preference weightings for calculation of QALYs from the SF-6D.12
Other evidence of the cost-effectiveness of manual or exercise therapy for the treatment of hip and knee OA is
scarce21, 22. The results reported here for the exercise therapy intervention are consistent with two recent
studies that assessed the cost-effectiveness of a physiotherapist-delivered class-based exercise programme and
a water exercise programme delivered by qualified swimming instructors, both of which found lower costs and
incremental QALY gains relative to usual care comparators23, 24. The findings extend our previously published
analyses of 1-year follow-up data from the MOA trial25. At 1 year, manual therapy and exercise therapy were
both found to be cost-effective relative to usual care only from both perspectives, and manual therapy costsaving from the societal perspective, while combined therapy was cost-effective only from the societal
perspective. This update shows that these gains are maintained and extended over 2 years, in particular for the

exercise therapy intervention. To our knowledge, no previous studies have assessed the cost-effectiveness of a
programme of supervised exercise physiotherapy or of manual physiotherapy in addition to usual care for the
treatment of hip or knee OA21. The external validity of this study, establishing the long-term effectiveness of this
highly generalizable intervention, compared with a real-world comparator, is a strength of this study.
Trials assessing the long-term clinical effectiveness of conservative therapies are also scarce; the little available
evidence indicates absence of long-term effect26, 27, 28, 29. The 2-year follow-up of this trial shows that the
treatment effect of exercise therapy can strengthen compared with usual care. Although we observed
diminishment of the treatment effects of the physiotherapy interventions over time in this subgroup [Fig. 3(b)],
notably, we observed deterioration in the subgroup of usual care patients who did not receive joint replacement
surgery (11·8 WOMAC points, 95% CI -3·2 to 26·8, unadjusted). This finding bears consideration when
interpreting long-term follow-up data of studies with alternative comparison populations. Our 2-year follow-up
shows that the gains from exercise therapy were maintained and extended over 2 years, compared with usual
care, while those of manual therapy were not, likely due to the active, self-efficacious nature of exercise
therapy. Maintenance and enhancement of the modest but significant treatment effect of conservative
therapies is an important new area of study. Building on very thin systematic review evidence28, data from our
trials and collaborations indicate that providing ‘booster sessions’ intended to reinforce patient adherence and
enhance treatment effects are an effective30 and cost-effective31 strategy when the clinical effectiveness of
exercise therapy is modest, but equivocal when the exercise therapy effect is stronger or follow-up shorter32, 33.
The results also corroborate evidence from our 1-year follow-up that, within a limited treatment session time,
single interventions result in better outcomes than combined interventions8. These results are consistent with
previous evidence that attempting to deliver too many modes of therapy in a restricted timeframe may
compromise the effective dose delivered of each component34, and provide no greater effect than an attentive
therapist delivering placebo and advice.35

Conclusions
Our findings indicate that the MOA trial exercise therapy intervention programme resulted in substantial health
gains to patients over 2 years of follow-up, was cost-effective at conventional willingness-to-pay thresholds, and
was cost-saving relative to usual care only from both the health system and societal perspectives. These findings
suggest that if health systems were to provide access to high-quality, individually supervised
exercise physiotherapy intervention programmes in addition to usual care, cost savings may be reaped through
reduced healthcare consumption and raised productivity.
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